Use of T Cell Mediated Immune Functional Assays for Adjustment of Immunosuppressive or Anti-infective Agents in Solid Organ Transplant Recipients: A Systematic Review
Open Access
- 15 October 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 567715
Abstract
Background Defining the optimal dosage of the immunosuppressive or duration of anti-infective agents is a challenge in solid organ transplant (SOT) recipients. We aimed to systematically review the literature regarding the use of T cell mediated immune functional assays (IFAs) for adjustment of the immunosuppressive or anti-infective agents in SOT recipients. Methods We systematically searched PubMed, Scopus, EMBASE, Web of Science (WOS), Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov to find human interventional studies or study protocols that used either in-house or commercially available IFAs for adjustment of the immunosuppressive or anti-infective agents in SOT recipients. Results We included six clinical trials and six study protocols. Four out of the six clinical trials used interferon-γ release assays for cytomegalovirus (IGRA-CMV), and five out of the six registered study protocols planned to use IGRA-CMV for adjustment of anti-CMV antiviral (Valganciclovir) prophylaxis or preemptive therapy in SOT recipients. Primary or secondary anti-CMV prophylaxes were discontinued in SOT recipients who had positive IGRA-CMV results without an increase in the rate of CMV infection or reactivation. Among other IFAs, one clinical trial used interferon-γ release assays for tuberculosis (IGRA-TB), and one study used ImmuKnow for adjustment of the duration and dosage of isoniazid and tacrolimus, respectively. Conclusion Our systematic review supports a promising role for the IGRA-CMVs for adjustment of the duration of anti-CMV antiviral prophylaxis in SOT recipients. There are limited data to support the use of IFAs other than IGRA-CMVs for adjustment of immunosuppressive or anti-infective agents. Further multicenter randomized clinical trials using IFAs other than IGRA-CMVs may help in personalized immunosuppressive or prophylactic anti-infective therapy in SOT recipients.Keywords
Funding Information
- Novo Nordisk Fonden
This publication has 51 references indexed in Scilit:
- ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta-analysisLiver Transplantation, 2012
- Can Immune Cell Function Assay Identify Patients at Risk of Infection or Rejection? A Meta-AnalysisTransplantation, 2012
- ATP synthesis and storagePurinergic Signalling, 2012
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Long-Term Care of the Liver Allograft RecipientSeminars in Liver Disease, 2009
- Cylex ImmuKnow Assay Levels Are Lower in Lung Transplant Recipients With InfectionThe Journal of Heart and Lung Transplantation, 2008
- Comparison of Sensitivities of Two Commercial Gamma Interferon Release Assays for Pulmonary TuberculosisJournal of Clinical Microbiology, 2008
- Limitations of the QuantiFERON®-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patientsEuropean Journal of Internal Medicine, 2008
- Quality of life after solid organ transplantationTransplantation Reviews, 2007
- Ex vivo monitoring of human cytomegalovirus‐specific CD8+ T‐cell responses using QuantiFERON®‐CMVTransplant Infectious Disease, 2007